VIDEO: Expert offers treatment guidelines for proliferative diabetic retinopathy

ByCarl D. Regillo, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

NEW YORK — In this presentation from OSN New York Retina, Carl D. Regillo, MD, of Wills Eye Hospital, provides guidelines for the treatment of proliferative diabetic retinopathy.

Regillo discussed treatment with panretinal photocoagulation vs. anti-VEGF therapy, as well as when to use both.

“These are guidelines based on the totality of data and my own way of looking at it,” Regillo said.

Published by:

Sources/Disclosures

Collapse

Source:

Regillo C. When to initiate therapy for proliferative diabetic retinopathy. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.

Disclosures: Regillo reports having financial disclosures for 4D Molecular Therapeutics, Adverum, Alcon, Allergan, Annexon, Apellis, Astellas, Aviceda, Clearside Biomedical, Cognition Therapeutics, EyePoint Pharmaceuticals, Genentech, Gyroscope, Iveric Bio, Janssen, jCyte, Kodiak Sciences, Lineage Cell Therapeutics, Merck, NGM Bio, Notal Vision, Novartis, Ocugen, Ocular Therapeutix, Ocuphire Pharma, OcuTerra, Opthea, Ray, Regeneron, Regenxbio, Stealth BioTherapeutics, Théa and Zeiss.

OSN New York and OSN New York Retina

Read more

VIDEO: Expert offers treatment guidelines for proliferative diabetic retinopathy

Related Content